On a consolidated basis, the company reported net sales for the second quarter of $406 million and adjusted EBITDA of $15 million.
We successfully completed our largest major maintenance outage of 2021 in April at our Lewiston, Idaho mill, which impacted the business by $22 million.
And finally, we maintained ample liquidity of $297 million at quarter end and reduced net debt by $4 million.
As you recall, we estimate that approximately 2/3 of paperboard demand is derived from products that are more recession-resilient and 1/3 is driven by more economically sensitive or discretionary products.
Since the beginning of this year, Fastmarkets RISI, a third-party industry publication recognized price increases that totaled $130 per ton in folding carton and $100 per ton in cup, including the latest increases in July of $30 per ton in folding and $50 per ton in carton.
The economic impact from this outage to our adjusted EBITDA was $22 million, within our previously discussed range of $21 million and $24 million.
The market for tissue in the U.S. is traditionally 2/3 at home and 1/3 away from home with around 10 million tons per year of total demand.
We shipped 10.2 million cases in the second quarter, which was down approximately 36% and 13% compared to the second quarter of 2020 and first quarter of 2021, respectively.
Our low point for shipments was 3.1 million cases in April.
In the second quarter of 2021, our net loss was $52 million.
Diluted net loss per share was $3.10 and adjusted loss per share of $1.07.
The impact of the Neenah aclosure activities in the quarter was $41.7 million.
The noncash portion of the charge, $36.9 million was primarily a fixed asset impairment, but also included inventory and other reserves.
The cash portion of the charge was for employee pay during a worn notification period and severance-related expenses of $4.9 million.
We anticipate that we will have similar employee-related cash expenses in the third quarter, slightly above $4 million.
Our Paperboard business completed a major maintenance outage in the second quarter of 2021 that impacted us by $22 million, while consumer products saw lower production and demand.
In our comments during the second quarter, we mentioned that our adjusted EBITDA could be close to breakeven for the second quarter of 2021 relative to the first quarter of 2021 adjusted EBITDA of $54 million.
With $15 million of adjusted EBITDA for the second quarter, we came in better than our initial expectations.
Our costs were impacted by the major maintenance outage of $22 million as well as inflation in raw material inputs and freight.
Our sales of converted products in the second quarter were 10.2 million cases, representing a unit decline of 36% versus prior year.
Our production of converted product in the quarter was 9.6 million cases or down 40% versus the prior year.
Our liquidity was $296.5 million at the end of the second quarter.
I would like to focus my comments for the third quarter expected adjusted EBITDA of $40 million to $48 million and build up to that range from our second quarter adjusted EBITDA of $15 million.
The planned major maintenance outage at Lewiston in April is behind us with a negative impact of $22 million.
And we recently completed the planned outage at Cypress Bend this past weekend with an anticipated impact of $3 million to $5 million.
The difference of the adjusted EBITDA impact between the second and third quarters resulted in an expected increase of adjusted EBITDA of $17 million to $19 million.
Previously, announced SBS pricing is expected to positively impact us during the quarter by $9 million to $11 million.
We estimate that raw material cost inflation will negatively impact our business by $9 million to $13 million in the third quarter relative to the second quarter.
Tissue shipments are expected to grow by 10% to 15% relative to the 10.2 million cases shipped in the second quarter.
We shipped 3.7 million cases in July relative to our average monthly shipments of 3.4 million in the second quarter and our low point of 3.1 million cases in April.
With the closure of Neenah, we are exiting the away-from-home tissue business, which was approximately 100,000 to 150,000 cases per month and will mildly impact our converted shipment volume trend lines and comparisons.
We are expecting continued positive impact from the previously announced SBS price increases were expected to result in year-over-year benefits of $40 million to $45 million.
In our Paperboard business, planned major maintenance outages are expected to reduce our earnings for 2021 compared to 2020 by $25 million to $27 million, which is down from our previous guidance.
Our current view can -- is that our tissue volume decline year-over-year will be above 20%, which is not adjusted for the impact of our exit from the away-from-home business.
In total, from 2020 to 2021 input cost inflation, including pulp, packaging, energy, chemicals and freight is expected to be $60 million to $70 million relative to our previous estimate of $65 million to $75 million.
In total, the benefit on a combined basis is expected to exceed $10 million annually with full benefit realization occurring in the fourth quarter.
For the full year 2021, we are also anticipating the following: we expect interest expense between $36 million and $38 million; depreciation and amortization between $104 million and $108 million; capital expenditures between $50 million and $55 million, which is slightly lower than prior expectations; and our effective tax rate is expected to be slightly higher than previous expectations at 26% to 27%.
Private brand tissue share in the U.S. rose to over 30% recently, up from 18% in 2011.
We look forward to sharing more on these ideas, which include internal investments, external investments and return of capital to shareholders as we get closer to our 2.5 times target leverage ratio.
